Omeros (OMER)
(Delayed Data from NSDQ)
$3.92 USD
-0.11 (-2.73%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.93 +0.01 (0.26%) 6:36 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Omeros Corporation [OMER]
Reports for Purchase
Showing records 381 - 400 ( 423 total )
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Q1 Cash Of $43.6 Million Can Last Into Q2 2012 Which Could Include Potential Partnerships.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
We Project Q1 Cash Of $43.6 Million Can Last Into Q2 2012 Which Could Include Potential Partnerships And Data Releases.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Failure in Knee Surgery Phase 3 Trials - Lowering Rating to Market Perform
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Company: Omeros Corporation
Industry: Medical - Products
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Omeros Corporation
Industry: Medical - Products
Failure in Knee Surgery Phase 3 Trials - Lowering Rating to Market Perform
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Company: Omeros Corporation
Industry: Medical - Products
Reducing Fair Value Due to Negative OMS103HP/ACL Phase 3.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 27
Provider: WEDBUSH SECURITIES INC.
Company: Omeros Corporation
Industry: Medical - Products
MORNING SUMMARY.
Provider: RODMAN & RENSHAW, CO.
Company: Omeros Corporation
Industry: Medical - Products
Raising Fair Value to $18 Due to Positive OMS302 Phase 2b Results.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Q4 Financials Were Uneventful. Imminent Release of Phase 3 Clinical Data Could Result in Significant Upside.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of March 6
Provider: WEDBUSH SECURITIES INC.
Company: Omeros Corporation
Industry: Medical - Products
Orphan GPCRs Unlock May Lead to Lucrative Partnership
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
MONTHLY PORTFOLIO UPDATE - ELEMER PIROS AND BORIS PEAKER
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E